Background and Purpose-The efficacy of the antiplatelet agent triflusal for prevention of vascular events after stroke has been reported in a pilot study. However, there is a need to confirm those results in a larger study. Methods-We performed a randomized, double-blind, multicenter study to test the efficacy of triflusal (600 mg/d) versus aspirin (325 mg/d) for prevention of vascular events in patients with stroke or transient ischemic attack (Triflusal versus Aspirin in Cerebral Infarction Prevention [TACIP]). We assessed a combined end point (incidence of nonfatal ischemic stroke, nonfatal acute myocardial infarction, or vascular death) as well as the incidence of these events separately and the incidence of major hemorrhage. Results-Of 2113 patients, 1058 received triflusal and 1055 aspirin. The mean follow-up period was 30.1 months. The incidence of combined end point (13.1% for triflusal, 12.4% for aspirin) as well the survival analysis (hazard ratio [HR] for triflusal versus aspirin, 1.09; 95% CI, 0.85 to 1.38) showed no differences between groups. The incidence of nonfatal stroke (HR, 1.09; 95% CI, 0.82 to 1.44), nonfatal acute myocardial infarction (HR, 0.95; 95% CI, 0.46 to 1.98,) and vascular death (HR, 1.22; 95% CI, 0.75 to 1.96) was also similar. A significantly higher incidence of major hemorrhages in the aspirin group was recorded (HR, 0.48; 95% CI, 0.28 to 0.82). The overall incidence of hemorrhage was significantly lower in the triflusal group (16.7% versus 25.2%) (odds ratio, 0.76; 95% CI, 0.67 to 0.86; PϽ0.001). Conclusions-This study failed to show significantly superior efficacy of triflusal over aspirin in the long-term prevention of vascular events after stroke, but triflusal was associated with a significantly lower rate of hemorrhagic complications.
A ntiplatelet agents are effective in the secondary prevention of stroke, 1 and aspirin is considered the first-line drug. 1 Other antiplatelet agents such as ticlopidine and clopidogrel or drug combinations (eg, aspirin and dipyridamole) have also been evaluated in this clinical setting. [2] [3] [4] Triflusal is an antiplatelet agent structurally related to aspirin that exerts its antithrombotic effect by acting on different targets involved in platelet aggregation and vascular inflammatory processes. [5] [6] [7] In addition, triflusal increases nitric oxide synthesis in neutrophils, resulting in increased vasodilatory potential. 8 Triflusal has already shown its efficacy in several thrombotic diseases. 9 -14 In a pilot study 15 comparing triflusal (900 mg/d) and aspirin (330 mg/d), the combined incidence of ischemic stroke, acute myocardial infarction (AMI), or vascular death was similar in both study groups, and there was a reduction of
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approximately 76% in hemorrhagic complications among triflusal-treated patients compared with the aspirin group (PϽ0.05). These data addressed the hypothesis that triflusal may have a better profile than aspirin in the long-term secondary prevention of stroke and justified the design and development of the present study. The aim of this trial was to assess the potential benefit of triflusal compared with aspirin.
Subjects and Methods

Participants
The Triflusal versus Aspirin in Cerebral Infarction Prevention (TACIP) Study was a prospective randomized, multicenter, doubleblind, aspirin-controlled trial that took place from March 1996 to September 1999 in 2 countries in Europe (Portugal and Spain) and involved the participation of 43 centers. Recruitment was completed in April 1997. The study was performed according to the Declaration of Helsinki and the European Good Clinical Practice guidelines. Study approval by local research ethics committees was obtained. Decisions regarding the study were made by a steering committee, which was assisted by an executive committee. A data-blind review committee appointed by the executive committee was responsible for validating all reported primary and secondary end points. An independent and masked contract research organization was responsible for coding the information on adverse events as recorded by the investigators according to the World Health Organization adverse reaction terminology. An independent external audit was performed, which did not detect any significant deviation (this guaranteed that the evaluated trial-related activities were conducted and the data were recorded, analyzed, and accurately reported according to the protocol, sponsor's standard operating procedures, good clinical practice, and applicable regulatory requirements).
Patients aged Ն40 years were eligible if they had suffered from a transient ischemic attack (TIA) or nondisabling stroke (Oxford Neurological Scale score Յ2) within the previous 6 months and had given written informed consent. TIA was defined as reversible ischemic neurological deficit with complete functional recovery within 24 hours; the clinical episode should have lasted Ͼ15 minutes, with at least 3 episodes within 24 hours for TIAs that lasted Ͻ15 minutes. Ischemic stroke was defined as a neurological deficit of vascular origin that persisted without functional recovery or with little improvement for Ͼ24 hours. A brain CT scan and/or MRI studies, preferably performed within the first month after the onset of symptoms, was required.
Main exclusion criteria were as follows: evidence of intracerebral hemorrhage or diagnosis of a nonatherothrombotic cause of stroke; history of endarterectomy or indication of this procedure after the qualifying cerebrovascular event; known hypersensitivity to salicylates; need for antiplatelet therapy because of previous ischemic heart disease; active peptic ulcer or history of upper gastrointestinal bleeding; liver or renal dysfunction; severe concomitant medical conditions; malignancy that may potentially increase the risk of hemorrhage; and chronic disorders requiring long-term treatment with systemic nonsteroidal anti-inflammatory drugs (NSAIDs), anticoagulants, or antiplatelet agents (anticoagulant or antiplatelet therapy until inclusion was not considered an exclusion criterion, only if the aim of the treatment was the vascular brain disease).
Design and Procedures
Patients were randomly assigned, in a double-blind fashion, to receive uncoated capsules of triflusal (600 mg/d) or aspirin (325 mg/d), prepared by Grupo Uriach, Barcelona, Spain. A random list was prepared by an independent statistical center. Treatment with triflusal or aspirin was allocated to the random codes by personnel unrelated to the study. Patients were treated for a minimum of 1 year and a maximum of 3 years.
At baseline, the following was recorded: demographic data, salient features of the qualifying cerebrovascular event, brain CT or MRI scan, general physical examination, chest roentgenograms, ECG, and standard laboratory tests. Follow-up visits were scheduled at days 30 and 90 after inclusion in the study and at 3-month intervals thereafter until visit 14 at month 36. At each visit, information regarding outcome events, adverse events, use of concomitant drugs, and compliance with the study medication was recorded. In addition, a closed questionnaire on possible adverse events regarding the gastrointestinal system and bleeding episodes was administered. Laboratory tests and ECG were repeated at months 12, 24, and 36. Treatment with NSAIDs was discouraged during the study. Treatment with any anticoagulant or antiplatelet agent other than the study drug was allowed only for periods not exceeding 7 days per year of patient inclusion in the study. All patients were followed until completion of the planned 3-year follow-up period even after the onset of a nonfatal primary end point (off medication) or therapy withdrawal.
Outcome Events
Primary outcome events included the first occurrence of vascular death, nonfatal ischemic stroke, or nonfatal AMI (Table 1) . Secondary end points were the occurrence of each of these events separately as well as overall mortality, nonvascular death, nonfatal ischemic stroke, any (fatal and nonfatal) ischemic stroke, nonfatal AMI, any AMI, nonfatal cerebral hemorrhage, any cerebral hemorrhage, major systemic hemorrhage (bleeding episode that required hospital admission and/or blood transfusion; any other bleeding was considered minor), any cerebral and major systemic hemorrhage, nonfatal systemic thromboembolism, and any systemic thromboembolism. Any event that led to death within 1 month of its occurrence was considered a fatal event.
Statistical Analyses
The planned sample size was 2062 patients. The expected incidence in the aspirin group was 18% on the basis of the observed 3-year incidence of vascular events. 1 With an expected loss to follow-up rate of 20% and a 2-sided ␣ϭ0.05, the study was expected to have 80% power to detect a clinically significant absolute reduction of at least 5% in the triflusal group (thus obtaining an absolute rate of vascular events of 13% in the triflusal arm). 16 Statistical analyses were performed for the intention-to-treat population (all randomized patients who had taken at least 1 dose of medication and had made at least 1 assessment of the efficacy variables) and the per-protocol population (with data of all patients while they were on medication). All data on outcome events recorded later than 30 days after permanent treatment discontinuation were censored in the per-protocol population. Survival curves were estimated with the Kaplan-Meier method, and differences were determined with the log-rank test. Cox proportional hazards models were used to estimate relative risks. Clinical end point risk estimates and 95% CIs for the primary and secondary outcome analyses were calculated. Statistical analyses were performed with the use of SAS Sudden death (death due to natural causes that takes place unexpectedly within a period of 24 hours from the onset of symptoms, in a previously healthy patient or affected by a process due to which short-term death was not predictable)
Ischemic stroke: any neurological deficit appeared after the qualifying event, which lasts more than 24 hours, and without evidence of brain hemorrhage in the head CT Acute myocardial infarction: this required the combination of at least 2 of the following criteria:
Chest pain suggestive of AMI Electrocardiographic criterion of AMI: presence of a new Q wave (lasting longer than 0.04 seconds or width Ͼ25% of the QRS complex), in at least one of the ECGs performed during the 24 hours following the onset of symptoms Enzymatic criterion of AMI: a rise of creatinphosphokinase of at least 2-fold above the upper normal limit during the 48 hours following the onset of symptoms (version 6.12). An independent statistical center performed the statistical analyses blindly.
Results
The trial profile is shown in Figure 1 . Of the 2113 patients randomized, 1058 were assigned to treatment with triflusal and 1055 to aspirin. Six patients (3 in each group) who did not take any dose of the study medication were excluded from the study. The intention-to-treat population consisted of 2107 patients (1055 received triflusal, 1052 received aspirin). The mean follow-up was 30.1 months. The per-protocol population included 2025 patients (1018 received triflusal, 1007 received aspirin) with a mean follow-up of 24.4 months. Study medication was early and permanently discontinued for reasons other than primary event or death in 590 patients (306 in the triflusal group, 284 in the aspirin group). Reasons for study drug discontinuation were similar in both groups and included, among others, nonserious adverse event (9.1%), patient's willingness (8.7%), or serious adverse event (5.9%).
No differences were noted between the treatment groups at baseline (Table 2 ). Most patients were male (65.8%), and the mean age (ϮSD) was 64.5 (Ϯ9.7) years. The qualifying cerebrovascular event was an ischemic stroke in 1557 patients (73.9%) (lacunar stroke in 52% of patients). Imaging studies included brain CT scans in 81.4% of patients, MRI in 7.6%, and both CT and MRI scans in 11%.
Two hundred sixty-eight patients (12.7%) suffered from an event defined as a primary end point of the study: 138 (13.1%) in the triflusal group and 130 (12.4%) in the aspirin group. The difference was not statistically significant. The survival analysis of triflusal versus aspirin showed a hazard ratio of 1.09 (95% CI, 0.85 to 1.38) (Figure 2 ). The perprotocol analysis showed a similar incidence of primary end point events without statistically significant differences. In respect to events defined as secondary end points of the trial, statistically significant differences were noted only in the incidence of bleeding episodes (Table 3) .
Moreover, following the definition of primary end point for clinical trials of antiplatelet drugs used in the Antithrombotic Trialists' Collaboration, 1, 17 we performed an analysis after we recalculated the primary end point in order to include nonfatal hemorrhagic strokes. The overall incidence in both groups did not change greatly: 140 of 1055 (13.3%) in the triflusal versus 136 of 1052 (12.9%) in the aspirin group (Pϭ0.87; odds ratio, 1.03; 95% CI, 0.80 to 1.33).
A total of 31 patients (2.9%) assigned to the aspirin group reported at least 1 major systemic hemorrhage compared with 13 (1.2%) in the triflusal group (relative risk reduction of 58%; 95% CI, 19% to 78%; Pϭ0.006). Any cerebral or major systemic hemorrhages were reported by 42 aspirin-treated patients (4.0%) and 20 triflusal-treated patients (1.9%) (Pϭ0.004), with a relative risk reduction of 52% (95% CI, 18% to 72%). Cumulative risk for any cerebral or major systemic hemorrhages is shown in Figure 3 . These findings were confirmed in the analysis of the per-protocol population.
A total of 1718 patients reported at least 1 adverse event (864 [81.2%] in the triflusal group and 854 [81.9%] in the aspirin group), with at least 1 serious adverse event associated with the study medication in 72 aspirin-treated patients (6.8%) and 60 triflusal-treated patients (5.7%) (Pϭ0.282). As shown in Table 4 , the majority of patients suffered from gastrointestinal complaints (39.8% versus 43.6% in the aspirin and triflusal groups, respectively); dyspepsia was significantly more frequently reported by patients given triflusal, while gastric or peptic ulcer occurred significantly more frequently among aspirin-treated subjects.
Patients treated with aspirin compared with triflusal showed a significantly higher overall incidence of hemorrhagic adverse events (25.2% versus 16.7%; odds ratio, 0.76; 95% CI, 0.67 to 0.86; PϽ0.001) as well as hemorrhagic adverse events related to the study medication (21.8% versus 13.7%; odds ratio, 0.74; 95% CI, 0.65 to 0.85; PϽ0.001). The incidence of minor bleeding was also significantly higher in the aspirin group (22.1%) than in the triflusal group (15.2%) (PϽ0.001).
Discussion
In this trial there were no statistically significant differences between triflusal and aspirin at administered doses regarding nonfatal ischemic stroke, nonfatal AMI, and vascular death with regard to either the combined incidence of these events or the incidence of each of them independently. The 95% CIs for the relative effect of triflusal versus aspirin were wide and included 1, and therefore the TACIP Study could not show a significantly superior efficacy of any treatment for the prevention of vascular events in this clinical setting. Instead, it showed that a substantial difference is unlikely. The incidence of major and minor bleeding episodes was significantly reduced by triflusal.
The results reported regarding baseline characteristics of both populations are in agreement with other studies. 18 -20 The distribution of men/women (66%/34%) and the percentage of patients who entered the study with TIA as a qualifying cerebrovascular accident (26%) are within the normally accepted limits in clinical trials on secondary prevention of stroke.
The study protocol was designed on the assumption of an incidence of primary end point of 18% in aspirin-treated patients, 1 whereas the results showed a final incidence of 12.4%. Several factors likely played a role (this lower incidence also occurred in other studies on stroke 19 ).
A nonsignificantly higher overall and vascular mortality was observed in the triflusal group, but in a previous randomized clinical trial in myocardial infarction 11 that compared triflusal and aspirin, a nonsignificant higher mortality was observed in the aspirin group, mainly in relation to vascular deaths.
After publication of the results from the first cooperative studies, aspirin has been considered the first-option drug in 
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the secondary prevention of stroke. 19 -24 Although other drugs have been reported in the medical literature to have similar [25] [26] [27] or even higher efficacy, 4,18,28,29 most therapeutic guidelines 30 -32 have maintained that aspirin is the first-choice drug because of its safety and price. Although some controversy still exists, treatment with aspirin at medium doses (75 to 325 mg/d) is the most widely accepted therapeutic regimen, and this regimen was also used in recent studies. 18, 19 Recent reviews of randomized trials of antiplatelet therapy 17, 33 did not find any significant difference regarding protective effects between high aspirin doses (500 to 1500 mg/d) and medium to low doses (30 to 325 mg/d). However, compared with medium doses, high doses of aspirin showed an increased risk of adverse gastrointestinal effects, while no significant differences were observed between medium (75 to 325 mg/d) and low doses (Ͻ75 mg/d). 34 There is no evidence that reducing the dose of aspirin would significantly lower its hemorrhagic risk. 35 Regarding hemorrhagic complications, their overall incidence was higher in the TACIP Study than in other similar studies. 19, 27, 36, 37 However, the incidence of major hemorrhages was similar. This may be due to the longer follow-up period or to the method of reporting adverse events, since the TACIP Study considered the incidence of hemorrhagic events as one of the secondary end points, and the case report form was carefully designed to collect any information about them.
The risk of aspirin treatment has probably been underestimated, especially when used for long-term therapy. 38 Results of the present study provide additional evidence to question the benefit/risk ratio of long-term use of aspirin.
Triflusal has shown a better safety profile than aspirin as a result of convincing evidence of lower hemorrhagic risk, that is, the incidence of major or minor bleeding episodes was significantly lower in the triflusal group, including gastrointestinal bleeding or skin hematomas. In addition, hemorrhages in any organ/system were less frequent among triflusal-treated patients. These findings are consistent with those reported in previous studies. 11, 15 Different reasons may explain why triflusal shows an antithrombotic effect with a lower incidence of hemorrhagic complications than aspirin. The inhibition exerted by triflusal on cyclooxygenase and subsequent release of thromboxane B 2 appears to be 10 times less than that of aspirin. 39 However, its additional mechanisms of action, such as inhibition of phosphodiesterase and of the release of nitric oxide by human neutrophils, 8 provide triflusal with enough antithrombotic activity to inhibit platelet hyperactivity observed in prothrombotic states but with preservation of platelet hemostatic function. In the clinical setting, the lack of prolongation of bleeding time by triflusal confirms the preservation of platelet function. 13 The incidence of dyspepsia was significantly lower in the aspirin group, although this did not seem to be clinically relevant because there were no differences regarding treatment withdrawal. In contrast, aspirin showed a significantly higher incidence of gastric/peptic ulcers. A possible explanation of this contradistinction may be that triflusal is a more acidic compound than aspirin (data on file, Grupo Uriach, Barcelona, Spain), and it probably causes gastric mucosal irritation after oral intake, leading to dyspepsia. On the other hand, the enhanced inhibition of cyclooxygenase by aspirin can lead to a lower synthesis of prostaglandin E 2 in the gastric mucosa, 7 thus reducing its protective mechanisms against acid and peptic enzymes and subsequently increasing the risk for peptic disease and gastrointestinal bleeding.
Triflusal is associated with a significantly lower incidence of major and minor hemorrhagic complications after longterm therapy with no differences in the incidence of primary efficacy end points. In our study triflusal could prevent 24 major hemorrhagic events (95% CI, 9 to 39) per 1000 patients treated with triflusal instead of aspirin, which is a relevant difference when one takes into account the personal burden of major hemorrhages. This finding may have a significant impact in clinical practice.
Triflusal may be safer than aspirin for long-term prevention of recurrent stroke. Moreover, it may be preferable for future trials evaluating the efficacy and safety of combinations of antiplatelet drugs for primary prevention of stroke in patients at vascular risk. 40 
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Editorial Comment Can Aspirin Ever Be Surpassed for Stroke Prevention?
Because of the modest benefit of aspirin for stroke prevention, 1,2 there continues to be interest in identifying more effective and safer agents. In this study, the investigators compared triflusal, an agent with a novel mechanism believed to be different from other antiplatelet drugs, with aspirin in over two thousand stroke patients. The study was appropriately, designed, powered, and executed to identify a clinically relevant difference in efficacy. Unfortunately, triflusal was no better than aspirin in preventing stroke recurrence. Obviously these results indicate that aspirin should remain the cornerstone of antiplatelet therapy for stroke prevention given its well-established clinically important benefit and very modest cost. Can we learn anything from the negative results of this study? Perhaps. Of importance, the study did report that the risk of cerebral hemorrhage was significantly lower using triflusal, but with a
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comparable level of stroke protection. This suggests that drugs with good stroke prevention capability are feasible, without increasing the risk of hemorrhagic complications as has been observed in studies of oral GP IIb-IIIa inhibitors in coronary artery disease patients. 3, 4 Certainly, if the cost of triflusal was comparable to aspirin, there might be justification for using this agent, given the substantial concern for hemorrhagic complications in our generally older, sicker stroke patients.
Will we ever find a drug that will truly outperform aspirin? Clearly in terms of cost effectiveness it will be hard to beat. Moreover, most head to head trials of single agents versus aspirin to date have shown little or no additional efficacy, as in triflusal study. The recently published data reporting no additional benefit for stroke prevention from warfarin (Warfarin Aspirin Recurrent Stroke Study [WARSS]), 5 or ticlopidine (African American Antiplatelet Stroke Prevention Study [AAASPS]) 6 versus aspirin clearly reflect this challenge.
What alternative strategies are on the horizon? Almost assuredly we will need to combine different antithrombotic agents. That such combinations may be more effective has already been suggested by the results of the European Stroke Prevention Study (ESPS-2) 7 in which the combination of aspirin and dipyridamole appeared to provide additional benefit compared with aspirin alone. Similarly, coronary studies of the combination of clopidogrel plus aspirin (Clopidogrel in Unstable Angina to prevent Recurrent Events [CURE]), 8 have reported additional beneficial effects on the prevention of coronary artery disease morbidity.
While controversy remains over the degree and applicability of the beneficial results observed in these and other studies, it is likely that stroke prevention regimens employing dual or multi-agent antithrombotic treatment will be successful in the future. Already 
